- Describe your topic.
- Therapies for Clinically Localized Prostate Cancer
- Describe why this topic is important.
- Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. Prostate cancer usually grows very slowly, finding and treating it early may improve men's health and help them live longer. With improved diagnostics early identification and treatment is even more important.
- Tell us why you are suggesting this topic.
- This topic was last reviewed by AHRQ in 2014 and significant advances in prostate treatment such as High Intensity Focused Ultrasound (HIFU) have been made since then. There are still healthcare stakeholders who reference the 2014 review even though it as been archived. There are also areas such as "salvage treatment" for patients with radio-recurrent prostate cancer which were not well covered in the previous review.
- Target Date.
- Describe what you are doing currently and what you are hoping will change because of a new evidence report.
- We are currently working with other HIFU manufacturers as well as the AUA to educate and encourage public and private insurers to gain reimbursement for FDA cleared devices for the non-invasive ablation of prostate tissue using image guided HIFU.
- How will you or your group use the information from a new evidence report?
- We would include reference to this information in packets for both patient and physician education.
- How would you or your group plan to disseminate information from the report? Who would you plan to disseminate it to?
- We would include the report in our packet of evidence along with both US and OUS clinical publications to support reimbursement decisions.
- Do you know of organizations that could use an evidence report to change clinical practice? Are you a part of, or have you been in contact with, any organizations that might implement the research findings of an evidence report?
- Yes, this could impact guidelines by organizations such as the American Urologists Association (AUA) or the National Comprehensive Cancer Network (NCCN). We have been communicating with the AUA on a regular basis to share developments in technology and clinical evidence from international peer reviewed publications.
- Information About You: (optional)
-
- Provide a description of your role or perspective.
- Regulatory executive with a HIFU device manufacturer
- If you are you making a suggestion on behalf of an organization, please state the name of the organization.
- EDAP Technomed, Inc.
- Please tell us how you heard about the Effective Health Care Program.
- AHRQ reference
